InflaRx (IFRX) Competitors $1.15 -0.10 (-8.00%) Closing price 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. RAPP, SLDB, HRTX, ALLO, ARCT, ATXS, GLUE, CYRX, AURA, and ESPRShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Rapport Therapeutics (RAPP), Solid Biosciences (SLDB), Heron Therapeutics (HRTX), Allogene Therapeutics (ALLO), Arcturus Therapeutics (ARCT), Astria Therapeutics (ATXS), Monte Rosa Therapeutics (GLUE), Cryoport (CYRX), Aura Biosciences (AURA), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Rapport Therapeutics Solid Biosciences Heron Therapeutics Allogene Therapeutics Arcturus Therapeutics Astria Therapeutics Monte Rosa Therapeutics Cryoport Aura Biosciences Esperion Therapeutics Rapport Therapeutics (NASDAQ:RAPP) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership. Does the MarketBeat Community believe in RAPP or IFRX? InflaRx received 240 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 65.05% of users gave InflaRx an outperform vote. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesInflaRxOutperform Votes24265.05% Underperform Votes13034.95% Is RAPP or IFRX more profitable? Rapport Therapeutics has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. Rapport Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A InflaRx -33,362.70%-65.98%-56.86% Does the media favor RAPP or IFRX? In the previous week, InflaRx had 4 more articles in the media than Rapport Therapeutics. MarketBeat recorded 9 mentions for InflaRx and 5 mentions for Rapport Therapeutics. InflaRx's average media sentiment score of 0.29 beat Rapport Therapeutics' score of 0.11 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in RAPP or IFRX? 42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, RAPP or IFRX? Rapport Therapeutics has higher earnings, but lower revenue than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79M-$13.84-0.73InflaRx$165.79K465.67-$46.18M-$0.87-1.32 Do analysts recommend RAPP or IFRX? Rapport Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 248.26%. InflaRx has a consensus target price of $9.00, indicating a potential upside of 682.61%. Given InflaRx's higher probable upside, analysts clearly believe InflaRx is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00InflaRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryInflaRx beats Rapport Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.20M$6.94B$5.64B$7.82BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-1.067.1723.1318.66Price / Sales465.67221.32388.4491.28Price / CashN/A65.6738.1634.64Price / Book0.616.396.894.23Net Income-$46.18M$142.12M$3.20B$247.15M7 Day Performance-10.16%-5.05%-2.94%-2.16%1 Month Performance-17.27%-7.39%1.71%-5.65%1 Year Performance-25.32%-8.74%9.83%-0.66% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.4084 of 5 stars$1.15-8.0%$9.00+682.6%-18.8%$77.20M$165,789.00-1.0660Analyst ForecastRAPPRapport Therapeutics1.7196 of 5 stars$10.22+5.1%$35.00+242.5%N/A$372.99MN/A-0.74N/AShort Interest ↑SLDBSolid Biosciences3.3787 of 5 stars$4.78+3.9%$15.67+227.8%-69.3%$370.42M$8.09M-1.57100Positive NewsHRTXHeron Therapeutics3.8469 of 5 stars$2.43+2.1%$5.67+133.2%-15.7%$370.16M$144.29M-13.50300Positive NewsALLOAllogene Therapeutics3.1992 of 5 stars$1.68+3.7%$9.29+452.9%-65.0%$365.01M$22,000.00-1.08310Positive NewsARCTArcturus Therapeutics3.0712 of 5 stars$13.27+3.0%$59.20+346.1%-63.5%$359.88M$138.39M-5.98180Positive NewsATXSAstria Therapeutics1.7627 of 5 stars$6.37-0.6%$26.67+318.6%-55.4%$359.49MN/A-3.0530Positive NewsGLUEMonte Rosa Therapeutics2.9719 of 5 stars$5.83+0.5%$15.50+165.9%-25.3%$358.18M$14.98M-3.1990Short Interest ↓CYRXCryoport2.527 of 5 stars$7.10+24.8%$11.67+64.3%-65.6%$354.36M$228.39M-2.101,020High Trading VolumeAURAAura Biosciences2.1349 of 5 stars$7.00-6.7%$23.00+228.6%-22.9%$349.66MN/A-4.0550Earnings ReportAnalyst RevisionNews CoverageHigh Trading VolumeESPREsperion Therapeutics3.8295 of 5 stars$1.74+3.0%$6.75+287.9%-38.5%$344.26M$332.31M-2.72200Analyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies Rapport Therapeutics Competitors Solid Biosciences Competitors Heron Therapeutics Competitors Allogene Therapeutics Competitors Arcturus Therapeutics Competitors Astria Therapeutics Competitors Monte Rosa Therapeutics Competitors Cryoport Competitors Aura Biosciences Competitors Esperion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
